SLC5A2 and type 2 diabetes mellitus: Our study findings suggested that insulin-receiving T2DM patients were at a higher risk of genital infections when exposed to SGLT-2 inhibitor therapy relative to metformin as comedication (adjusted OR 1.76, p = 0.03).